449 results on '"Regueiro, Miguel D."'
Search Results
2. S902 Assessing the Impact of Interval Duration Between Ileal Pouch Creation and Loop Ileostomy Closure on the Development of Subsequent Inflammatory Pouch Conditions in Patients with Ulcerative Colitis
3. Preoperative Use of Multiple Advanced Therapies Is Not Associated With Endoscopic Inflammatory Pouch Diseases.
4. Altered Expression of the Epithelial Mucin MUC1 Accompanies Endoscopic Recurrence of Postoperative Crohn’s Disease
5. 948 ETRASIMOD FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 2.5 YEARS OF POOLED SAFETY DATA FROM GLOBAL CLINICAL TRIALS
6. Preoperative Use of Multiple Advanced Therapies Is Not Associated With Endoscopic Inflammatory Pouch Diseases
7. Ulcerative colitis–risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study
8. Teleconferences to Facilitate Multidisciplinary Care and Education in IBD
9. White Paper AGA: The Impact of Mental and Psychosocial Factors on the Care of Patients With Inflammatory Bowel Disease
10. Approach to Latent Tuberculosis Infection Screening Before Biologic Therapy in IBD Patients: PPD or IGRA?
11. Treatment of Distal/Left-Sided Ulcerative Colitis
12. Predictors of Suicidal Ideation Among IBD Outpatients
13. Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial
14. Pediatric autoimmune enteropathy: an entity frequently associated with immunodeficiency disorders
15. Distinct Histopathologic and Molecular Alterations in Inflammatory Bowel Disease-Associated Intestinal Adenocarcinoma: c-MYC Amplification is Common and Associated with Mucinous/Signet Ring Cell Differentiation
16. IBD LIVE Case Series: Case 9: Do Race and Extraintestinal Manifestations Affect Treatment of Severe Crohn’s Colitis?
17. It’s Too Soon to Count Out Vedo for Postoperative Crohn’s Disease
18. IBD LIVE Series—Case 8: Treatment Options for Refractory Esophageal Crohnʼs Disease and Hidradenitis Suppurativa
19. 719: POSTOPERATIVE CROHN'S DISEASE RECURRENCE RISK AND OPTIMAL BIOLOGIC TIMING AFTER TEMPORARY DIVERSION FOLLOWING ILEOCECAL RESECTION
20. Sa1605: CLINICAL CHARACTERISTICS, MEDICATION UTILIZATION, AND CLINICAL OUTCOMES OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND HEART FAILURE: A MULTICENTER NETWORK STUDY
21. Mo1545: IMPACT OF BIOLOGICS THERAPY ON THE PREVALENCE OF DEMENTIA AMONG OLDER PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A NATIONWIDE POPULATION-BASED STUDY
22. 720: EARLY INITIATION OF ANTI-TUMOR NECROSIS FACTOR THERAPY REDUCES POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE FOLLOWING ILEOCECAL RESECTION
23. Sa1591: INTRAABDOMINAL SEPTIC COMPLICATIONS AFTER ILEOCOLIC RESECTION INCREASES ENDOSCOPIC POSTOPERATIVE CROHN'S DISEASE RECURRENCE
24. Mo1555: PRE-OPERATIVE USE OF MULTIPLE BIOLOGIC AND SMALL MOLECULE DRUGS IS NOT ASSOCIATED WITH SUBSEQUENT ENDOSCOPIC INFLAMMATORY POUCH DISEASES
25. Tu1472: RAPIDITY OF OZANIMOD-INDUCED SYMPTOMATIC RESPONSE AND REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE INDUCTION PERIOD OF TRUE NORTH
26. 456: CHRONOLOGIC AGE IS NOT ASSOCIATED WITH RISK OF POSTOPERATIVE RECURRENCE IN CROHN'S DISEASE
27. 15: LONG-TERM CARDIAC SAFETY OF OZANIMOD IN PHASE 3 CLINICAL PROGRAM OF ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS
28. Tu1450: EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
29. Sa1604: CLINICAL CHARACTERISTICS, DISEASE-SPECIFIC OUTCOMES, AND MEDICATION UTILIZATION AMONG PATIENTS WITH ULCERATIVE COLITIS AND MULTIPLE SCLEROSIS IN THE USA: A MULTICENTER NETWORK STUDY
30. Sa1603: CLINICAL CHARACTERISTICS, DISEASE-SPECIFIC OUTCOMES, AND MEDICATION UTILIZATION AMONG PATIENTS WITH CHRON'S DISEASE AND MULTIPLE SCLEROSIS IN THE USA: A MULTICENTER NETWORK STUDY
31. Tu1448: EFFECT OF BASELINE DISEASE CHARACTERISTICS ON CLINICAL OUTCOMES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS TREATED WITH UPADACITINIB: RESULTS FROM A PHASE 3 TRIALS PROGRAMME
32. Mo1563: POST-OPERATIVE IMMUNOSUPPRESSIVE THERAPY FOLLOWING ILEAL POUCH ANAL ANASTOMOSIS CREATION: AN ASSESSMENT USING THE TRINETX COHORT
33. 401: ANASTOMOTIC CONFIGURATION AND DIVERTING OSTOMY DOES NOT INCREASE THE RISK OF POSTOPERATIVE ANASTOMOTIC STRICTURES IN CROHN'S DISEASE
34. Tu1852 DIVORCE AND WIDOWHOOD NEGATIVELY IMPACT INFLAMMATORY BOWEL DISEASE - A NATIONWIDE COHORT ANALYSIS
35. Su1797 ETRASIMOD SHOWS LOW RISK OF ADVERSE EVENTS FOLLOWING CONCOMITANT USE WITH OPIOIDS OR ANTIDEPRESSANTS IN PATIENTS WITH ULCERATIVE COLITIS
36. Su1791 DURABILITY OF RESPONSE IN DELAYED RESPONDERS TO OZANIMOD IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY NUMBER OF PRIOR BIOLOGICS: 3-YEAR UPDATE FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
37. 763 RISANKIZUMAB VERSUS USTEKINUMAB FOR THE ACHIEVEMENT OF CLINICAL REMISSION AND REDUCTION IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE TRIAL
38. Sa1777 IBD PATIENTS CONCOMITANTLY TREATED WITH GLP1 AGONISTS HAD FEWER HOSPITALIZATIONS AND DISEASE RELATED COMPLICATIONS: A US COHORT PROPENSITY-MATCHED STUDY
39. Sa1754 PARADOXICAL RISK OF RHEUMATOID ARTHRITIS IN INFLAMMATORY BOWEL DISEASE PATIENTS EXPOSED TO TUMOR NECROSIS FACTOR INHIBITORS: A PROPENSITY MATCHED MULTI-NETWORK STUDY
40. Sa1743 BIOLOGICS AND ORAL SMALL MOLECULES ARE NOT ASSOCIATED WITH INCREASED MAJOR ADVERSE CARDIOVASCULAR EVENTS OR VENOUS THROMBOEMBOLISM IN OLDER IBD PATIENTS
41. Sa1011 PATIENTS WITH INFLAMMATORY BOWEL DISEASE WHO SPEAK A NON-ENGLISH PRIMARY LANGUAGE HAVE HIGHER RATES OF UNPLANNED CARE AND LOWER USE OF ADVANCED THERAPIES: A POPULATION-BASED MULTI-NETWORK ANALYSIS
42. Tu1887 EFFICACY AND SAFETY OF SEMAGLUTIDE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND OBESITY
43. Tu1883 CHARACTERISTICS AND PREDICTORS OF LONG-TERM REMITTERS AFTER ILEOCOLONIC RESECTION FOR CROHN'S DISEASE
44. 720 ORAL SMALL MOLECULES ARE NOT ASSOCIATED WITH INCREASED CANCER RATES IN IBD PATIENTS
45. 246 COST-EFFECTIVENESS OF A BIOMARKER MONITORING STRATEGY COMPARED TO ENDOSCOPIC MONITORING IN LOW-RISK POSTOPERATIVE CROHN'S DISEASE.
46. Mo1841 RATES OF ESCALATION TO ADVANCED THERAPY IN PATIENTS WITH ULCERATIVE PROCTITIS AT SIX MONTHS, ONE YEAR, AND TWO YEARS POST DIAGNOSIS
47. Mo1353 MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) AND VENOUS TROMBOEMBOLISM (VTE) ARE NOT INCREASED IN MICROSCOPIC COLITIS: A PROPENSITY MATCHED MULTI-NETWORK STUDY
48. Su1853 INCREASED PSYCHIATRIC COMORBIDITIES AND RISK OF SUICIDE IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE 6-12 MONTHS AFTER INITIAL DIAGNOSIS: A MULTI-NETWORK PROPENSITY-MATCHED COHORT STUDY
49. 1095 EXHALED BREATH ANALYSIS OF VOLATILE ORGANIC COMPOUNDS IS ASSOCIATED WITH LUMINAL DISEASE ACTIVITY IN PATIENTS WITH ULCERATIVE COLITIS
50. Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.